PT  - JOURNAL ARTICLE
AU  - Anna-Mária Tökés
AU  - A Marcell Szász
AU  - Franciska Geszti
AU  - Lilla V Lukács
AU  - István Kenessey
AU  - Eszter Turányi
AU  - Nóra Meggyesházi
AU  - István A Molnár
AU  - János Fillinger
AU  - Ibolya Soltész
AU  - Katalin Bálint
AU  - Zoltán Hanzély
AU  - Gabriella Arató
AU  - Miklós Szendröi
AU  - Janina Kulka
TI  - Expression of proliferation markers Ki67, cyclin A, geminin and aurora-kinase A in primary breast carcinomas and corresponding distant metastases
AID  - 10.1136/jclinpath-2014-202607
DP  - 2015 Apr 01
TA  - Journal of Clinical Pathology
PG  - 274--282
VI  - 68
IP  - 4
4099  - http://jcp.bmj.com/content/68/4/274.short
4100  - http://jcp.bmj.com/content/68/4/274.full
SO  - J Clin Pathol2015 Apr 01; 68
AB  - Aims To assess the expression of the following cell cycle regulatory proteins in primary metastatic breast carcinomas (MBCs) and on availability in matched distant metastases (DMs): Ki67, cyclin A, geminin and aurora-kinase A (aurkA); and to compare the expression of these markers in early MBC (EMBC) and late MBC separated into groups according to median time point on metastatic event occurred (28 months). Methods The expression of the above mentioned markers was analysed in a total of 47 primary MBCs and 59 DMs (out of which 37 were pairs) by immunohistochemistry. Fourteen breast carcinomas with no relapse over a 10-year follow-up period were utilised as control cases (CBC). Results Among the MBCs, 22 metastasised to the bone, 4 to the lung and 21 to the central nervous system (CNS). Geminin (p<0.001) and Ki67 (p=0.001) were increased in the MBCs while aurkA and cyclin A showed no difference when compared with CBCs. There were no differences between aurkA, cyclin A and geminin expression in MBCs and DMs in general. Expression of Ki67 was, however, elevated (p=0.027) in DMs. In CNS metastases all markers showed elevated expression as compared to MBCs. In bone metastases, geminin was lower (p<0.001) compared with primary MBCs. In the metastases of the lung, the evaluated markers did not show different expression. According to the median follow-up until the metastatic event, Ki67 was found to be significantly elevated in EMBC (p=0.018). Conclusions Ki67 index and geminin distinguish a fraction of MBC with worse prognosis, showing increased levels in the latter in comparison to CBC being tumour-free over a 10-year follow-up period. Ki67 could possibly identify a group of MBCs that develop early DMs.